tenofovir has been researched along with Adverse Drug Event in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (12.77) | 29.6817 |
| 2010's | 36 (76.60) | 24.3611 |
| 2020's | 5 (10.64) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Hughes, C | 1 |
| Chen, L; Liu, X; Zhao, L | 1 |
| Hemmingsson, P; Lodin, K; Rosenborg, S | 1 |
| Abbasian, L; Alavian, G; Alinaghi, SAS; Ashtiani, MF; Hasannezhad, M; Khalili, H; Manshadi, SAD | 1 |
| Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N | 1 |
| Bakshi, RP; Coleman, JS; Fuchs, EJ; Hendrix, CW; Marzinke, MA; Robinson, JA; Rohan, LC; Spiegel, HML | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K | 1 |
| Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
| Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
| Asiimwe, S; Baeten, JM; Bukusi, EA; Bulya, N; Celum, C; Heffron, R; Hong, T; Katabira, E; Marzinke, MA; Mugo, N; Ngure, K; Odoyo, J; Tindimwebwa, E | 1 |
| Chao, Y; Hou, MC; Huang, YH; Lan, KH; Lee, IC; Li, CP; Lin, HC; Su, CW | 1 |
| Boulle, A; Cohen, K; Davies, MA; de Waal, R; Fox, MP; Igumbor, EU; Maartens, G | 1 |
| Aslan, A; Balavoine, S; Bauer, R; Brun, A; Delaugerre, C; Leplatois, A; Loze, B; Molina, JM; Moudachirou, K; Noret, M; Pintado, C; Rozenbaum, W; Siguier, M | 1 |
| Ahmed, K; Baron, D; Bekker, LG; Brown, ER; Brumskine, W; Delany-Moretlwe, S; Doncel, GF; Gray, G; Lombard, C; Marzinke, M; Morris, L; Myer, L; Nchabeleng, M; Nkala, B; Ntshangase, J; Palanee-Philips, T; Panchia, R; Rees, H; Schwartz, JL; Sebe, M; Sibiya, S; Smith, E | 1 |
| Akarca, US; Caruntu, FA; Celen, MK; Cornberg, M; Curescu, MG; Dienes, HP; Erhardt, A; Gürel, S; Hardtke, S; Heidrich, B; Idilman, R; Keskin, O; Koch, A; Lüth, S; Manns, MP; Mederacke, I; Papatheodoridis, GV; Port, K; Radu, M; Stift, J; von der Leyen, H; Weber, K; Wedemeyer, H; Wittkop, U; Yalcin, K; Yurdaydin, C; Zeuzem, S | 1 |
| Di Perri, G; Esser, S; Lelièvre, JD; Parczewski, M; Shafran, SD | 1 |
| Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G | 1 |
| Bekker, LG; Kaplan, R; Lawn, SD; Njuguna, C; Orrell, C; Wood, R | 1 |
| De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N | 1 |
| Alt, C; Shankar, GN | 1 |
| Chen, CW; Chen, SJ; Cheng, J; Dong, J; Gao, ZL; Hou, JL; Ji, Y; Jia, JD; Li, J; Mao, Q; Mao, YM; Ning, Q; Niu, JQ; Pan, C; Ren, H; Sheng, JF; Tan, DM; Tang, H; Wang, H; Wu, SM; Xie, Q; Xu, M; Zhang, JM; Zhang, XX; Zhao, W | 1 |
| Aurpibul, L; Puthanakit, T | 1 |
| Andreatta, KN; Da Silva, MT; De Aquino, MZ; De Carvalho, AP; Della Negra, M; Graham, B; Liu, YP; Pinto, JA; Quirk, EK | 1 |
| Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O | 1 |
| Arterburn, S; Castaño, E; Cheng, AK; Chuck, SL; Church, J; Deville, J; Enejosa, JV; Estripeaut, D; Gaur, A; Rathore, M; Rhee, MS; Saez-Llorens, X; White, K | 1 |
| Chang, KC; Chen, CH; Chiu, KW; Chou, YP; Hu, TH; Hung, CH; Lee, CM; Lin, MT; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH; Yen, YH | 1 |
| Abebe, KZ; Aung, WS; Bakshi, RP; Breakey, JC; Caffo, BS; Du, Y; Fuchs, EJ; Hendrix, CW; Hiruy, H; Manohar, M; Marzinke, MA; McGowan, I; Rohan, LC; Spiegel, HM; Yue, C | 1 |
| Bedu-Addo, G; Chadwick, DR; Kirk, ES; Owusu, AL; Owusu, D; Parris, V; Phillips, R; Sarfo, FS | 1 |
| Aguiar, C; Antela, A; Boffito, M; Compston, J; Di Perri, G; Hendry, BM; Mallon, P; Pourcher-Martinez, V | 1 |
| Gazzard, B | 1 |
| Baggaley, RC; Mameletzis, I; Mofenson, LM | 1 |
| Andrade, L; Libório, AB; Pereira, LV; Sanches, TR; Seguro, AC; Shimizu, MH | 1 |
| Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S | 1 |
| Amin, J; Baker, D; Bloch, M; Carr, A; Cooper, DA; Emery, S; Martin, A | 1 |
| Reiss, P | 1 |
| Brown, LB; Eron, JJ; Hosseinipour, MC; Kumwenda, JJ; Mhango, B; Mzinganjira, D; Phiri, S; van Oosterhout, JJ; Weigel, R | 1 |
| Chambers, MG; Earnshaw, SR; Farkouh, RA; Kauf, TL; Maroudas, P; Watson, ME | 1 |
| Chen, J; Cho, S; Cohen, HW; Diament, EC; Fazzari, MJ; Hendrix, CW; Herold, BC; Kalyoussef, S; Keller, MJ; Lee, AC; Louissaint, N; Madan, RP; Mesquita, PM; Shust, G; Soto-Torres, L; Torres, NM | 1 |
| Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
| Grulich, AE; Poynten, IM; Zablotska, I | 1 |
| McGowan, I | 1 |
| Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O | 1 |
| Hussar, DA | 1 |
| Cheng, AK; Ebrahimi, R; Kearney, BP; Mathias, A; Mittan, A; Sayre, J | 1 |
8 review(s) available for tenofovir and Adverse Drug Event
| Article | Year |
|---|---|
Renal adverse drug reactions.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Tenofovir | 2021 |
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
Topics: Adenine; Administration, Oral; Alanine; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Guanine; Hepatitis B, Chronic; Humans; Nucleosides; Randomized Controlled Trials as Topic; Tenofovir; Time Factors; Treatment Outcome | 2018 |
Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.
Topics: Adenine; Age Factors; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Comorbidity; Disease Management; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Life Style; Tenofovir; Treatment Outcome | 2019 |
Review of tenofovir use in HIV-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Bone and Bones; Child; Child, Preschool; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Kidney; Organophosphonates; Tenofovir; Young Adult | 2015 |
The role of tenofovir alafenamide in future HIV management.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Prodrugs; Tenofovir; Treatment Outcome | 2016 |
Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Disease Transmission, Infectious; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Pre-Exposure Prophylaxis; Pregnancy; Tenofovir | 2017 |
Considerations regarding antiretroviral chemoprophylaxis in MSM.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Organophosphonates; Plasma; Tenofovir; Treatment Outcome | 2012 |
Rectal microbicide development.
Topics: Adenine; Administration, Rectal; Administration, Topical; Anilides; Anti-HIV Agents; Chemoprevention; Clinical Trials, Phase I as Topic; Drug-Related Side Effects and Adverse Reactions; Furans; HIV Infections; Homosexuality, Male; Humans; Male; Organophosphonates; Tenofovir; Thioamides | 2012 |
16 trial(s) available for tenofovir and Adverse Drug Event
| Article | Year |
|---|---|
Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial.
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Pilot Projects; RNA; Tenofovir; Treatment Outcome | 2023 |
Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
Topics: Administration, Intravaginal; Adult; Anti-HIV Agents; Cervix Uteri; Chemoprevention; Cross-Over Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Plasma; Pre-Exposure Prophylaxis; Tenofovir; Time Factors; Vagina; Vaginal Creams, Foams, and Jellies; Young Adult | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir | 2018 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Anti-HIV Agents; Disease Transmission, Infectious; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Placebos; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies | 2018 |
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Hepatitis D; Hepatitis Delta Virus; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Recurrence; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2019 |
Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Deoxycytidine; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Zidovudine | 2013 |
Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Asian People; China; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Child; Double-Blind Method; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Placebos; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2015 |
A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Topics: Adenine; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2015 |
A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).
Topics: Administration, Rectal; Adult; Anti-HIV Agents; Cross-Over Studies; Disease Transmission, Infectious; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Gels; HIV Infections; Humans; Male; Middle Aged; Plasma; Tenofovir; Unsafe Sex | 2015 |
Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Causality; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Female; Ghana; HIV Infections; Humans; Kidney Diseases; Male; Middle Aged; Prevalence; Proteinuria; Risk Assessment; Tenofovir | 2015 |
Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; India; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; Treatment Outcome; Young Adult | 2008 |
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HLA-B Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Genitalia, Female; HIV Infections; Humans; Immunity, Mucosal; Mucous Membrane; Organophosphonates; Semen; Tenofovir; Vaginal Douching; Young Adult | 2011 |
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.
Topics: Adenine; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Organophosphonates; Ritonavir; Saquinavir; Tenofovir | 2006 |
23 other study(ies) available for tenofovir and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
[Study on mining of signals of adverse drug reactions of entecavir and tenofovir disoproxil based on the US FAERS database].
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Humans; Infant, Newborn; Male; Tenofovir; United States; United States Food and Drug Administration | 2021 |
Topics: Drug-Related Side Effects and Adverse Reactions; Fanconi Syndrome; Humans; Tenofovir | 2023 |
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2018 |
Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention.
Topics: Adult; Anti-HIV Agents; Child Development; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant, Newborn; Kenya; Longitudinal Studies; Maternal-Fetal Exchange; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Outcome; Tenofovir; Uganda | 2018 |
Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antiviral Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Humans; Incidence; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Assessment; Tenofovir | 2018 |
Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Kaplan-Meier Estimate; Retrospective Studies; South Africa; Stavudine; Tenofovir | 2018 |
Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; Hospitals; Humans; Incidence; Male; Outpatients; Paris; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Behavior; Tenofovir | 2018 |
Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Primary Health Care; Retrospective Studies; Risk Factors; South Africa; Tenofovir | 2013 |
Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Plasma; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
Topics: Acrylic Resins; Acyclovir; Adenine; Animals; Anti-Infective Agents; Chlorocebus aethiops; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Female; Herpes Genitalis; Herpesvirus 2, Human; Mice, Inbred BALB C; Organophosphonates; Poloxamer; Rabbits; Rats, Sprague-Dawley; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Vero Cells | 2014 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Urinalysis; Viral Load | 2015 |
Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Treatment Outcome | 2016 |
Editorial.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Tenofovir | 2016 |
Rosiglitazone reverses tenofovir-induced nephrotoxicity.
Topics: Adenine; Animals; Drug-Related Side Effects and Adverse Reactions; Glomerular Filtration Rate; Hypoglycemic Agents; Hypophosphatemia; Hypophosphatemia, Familial; Kidney Diseases; Male; Membrane Transport Proteins; Organophosphonates; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rosiglitazone; Tenofovir; Thiazolidinediones | 2008 |
The art of managing human immunodeficiency virus infection: a balancing act.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2009 |
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Body Mass Index; CD4 Lymphocyte Count; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; HIV Infections; HIV-1; Humans; Malawi; Male; Medication Adherence; Middle Aged; National Health Programs; Organophosphonates; Prospective Studies; RNA, Viral; Statistics as Topic; Tenofovir; Treatment Failure; Tuberculosis; Urban Population; Viral Load; Zidovudine | 2010 |
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Dideoxynucleosides; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Genetic Testing; HIV Infections; HLA-B Antigens; Humans; Middle Aged; Models, Economic; Organophosphonates; Quality-Adjusted Life Years; Tenofovir; United States | 2010 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Blood Chemical Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Turkey | 2013 |
New drugs 2002, part III.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid | 2002 |